iNewz.in Hindi News

Us Uk Trust: Now It Is The Turn Of The Children S Armor, The Vaccine Is Being Vaccinated In Many Countries

{“_id”:”61808f61226f451e3f0e6ce3″,”slug”:”us-uk-trust-now-it-is-the-turn-of-the-children-s-armor-the-vaccine-is-being-vaccinated- in-many-countries”,”type”:”story”,”status”:”publish”,”title_hn”:”Children’s ‘armor’: US-UK express confidence, children can be planted in many countries Commentary”,”category”:{“title”:”World”,”title_hn”:”world”,”slug”:”world”}}

Amar Ujala Research Team, New Delhi.

Published by: Yogesh Sahu
Updated Tue, 02 Nov 2021 06:37 AM IST

Summary

The country is slowly getting free from the clutches of the corona epidemic and is breathing a sigh of relief. On the occasion of worship of Lord Dhanvantari, we all have the responsibility that we should not let this new ray of hope blur due to any kind of carelessness and do not give an opportunity to the epidemic to raise its head again. It is necessary that keeping in mind the instructions of experts, this festival of lights should be celebrated with social distance, masks and all other precautions.

symbolic picture.
– Photo : Social Media

The world’s largest corona vaccination campaign running in the country has crossed the 100 crore mark. Now it is the turn to apply ‘Kavach’ to protect children from corona. The Subject Expert Committee (SEC) of the Government of India has agreed to two vaccines after studying the data. So let us know which vaccines are there in the country which will become a shield for children in future.

covaxin
Bharat Biotech’s vaccine, Covaxin, has been recommended for children aged 2 to 18 years. This will be the country’s first indigenous vaccine, which will be administered to children. It is 65.2% effective in protecting against the Delta variant.

Speciality

  • Vaccines have been tested on 525 children
  • Testing was also done on children of 2 to 6 years
  • 77.8 percent of vaccine-effective children
  • Both doses have to be administered in 28 days.

Covaxin Children’s Armor

The test results show that Covaxin will become a protective shield for them in the coming times. No significant side effects have been observed. The vaccine is safe and effective. -Doctor. Krishna Ella, Managing Director, Bharat Biotech

zydus cadilla
Pharma company Zydus Cadila’s vaccine Zycov-D has been approved for use in children above 12 years of age. This is the world’s first DNA vaccine, which will be available to both children and adults in the coming times.

Speciality

  • 0-28-28 Three doses will be taken in the day
  • Effective in 66 to 67 percent of adults
  • Vaccine is 100% effective in children
  • Vaccines have been tested on 1400 children

Children’s immune system strong

The Xycov-D vaccine is 100% effective and safe in children. This is because the immune system of children has been seen to be stronger than that of adults. -Doctor. Sharvil Patel, Managing Director, Zydus Cadila

kovavax
US company Novavax’s vaccine is being tested in India on children aged 12 to 17 at the Serum Institute of India in Pune. In India it will be known as Kovavax. Permission is pending in the US.

  • Claim: Novavax claims that this vaccine is 100% effective in protecting against moderate and severe infections in children. On average, this vaccine is 90.4% effective.
  • testing: Research continues on 100 children at KEM Hospital in Mumbai and Bharati Vidyapeeth Hospital in Pune. The results of the Phase II trial are awaited.
  • biological E : The Phase II and III trials of the pharma company’s vaccine, Corbevax, are underway on children aged five to 18 years.
  • Dosage: For 30 crore doses, the central government has already given 1500 crore rupees in advance.
  • testing : The vaccine has been allowed to be tested on children between the ages of 5 and 18. Sick children are also to be included in the test.

Children’s population in India at a glance

  • More than 44 crore children are older than two years in the country
  • 12 crore children are 12 to 17 years old in the country
  • 20 to 30 lakh children are suffering from some disease

Sick children get priority

Sick children should get priority in vaccination. If such children come in the grip of infection, then their life can be in trouble. The risk to healthy children is low, but it is important to vaccinate them over time. -Doctor. Gagandeep Kang, Scientist, Christian Medical College, Vellore

Expansion

The world’s largest corona vaccination campaign running in the country has crossed the 100 crore mark. Now it is the turn to apply ‘Kavach’ to protect children from corona. The Subject Expert Committee (SEC) of the Government of India has agreed to the two vaccines after studying the data. So let us know which vaccines are there in the country which will become a shield for children in future.

covaxin

Bharat Biotech’s vaccine, Covaxin, has been recommended for children aged 2 to 18 years. This will be the country’s first indigenous vaccine, which will be administered to children. It is 65.2% effective in protecting against the Delta variant.

Speciality

  • Vaccines have been tested on 525 children
  • Testing was also done on children of 2 to 6 years
  • 77.8 percent of vaccine-effective children
  • Both doses have to be administered in 28 days.

Covaxin Children’s Armor

The test results show that Covaxin will become a protective shield for them in the coming times. No significant side effects have been observed. The vaccine is safe and effective. -Doctor. Krishna Ella, Managing Director, Bharat Biotech

zydus cadilla

Pharma company Zydus Cadila’s vaccine Zycov-D has been approved for use in children above 12 years of age. This is the world’s first DNA vaccine, which will be available to both children and adults in the coming times.

Speciality

  • 0-28-28 Three doses will be taken in the day
  • Effective in 66 to 67 percent of adults
  • Vaccine is 100% effective in children
  • Vaccines have been tested on 1400 children

Children’s immune system strong

The Xycov-D vaccine is 100% effective and safe in children. This is because the immune system of children has been seen to be stronger than that of adults. -Doctor. Sharvil Patel, Managing Director, Zydus Cadila

kovavax

US company Novavax’s vaccine is being tested in India on children aged 12 to 17 at the Serum Institute of India in Pune. In India it will be known as Kovavax. Permission is pending in the US.

  • Claim: Novavax claims that this vaccine is 100% effective in protecting against moderate and severe infections in children. On average, this vaccine is 90.4% effective.
  • testing: Research continues on 100 children at KEM Hospital in Mumbai and Bharati Vidyapeeth Hospital in Pune. The results of Phase II trials are awaited.
  • biological E : The Phase II and III trials of the pharma company’s vaccine, Corbevax, are underway on children aged five to 18 years.
  • Dosage: For 30 crore doses, the central government has already given 1500 crore rupees in advance.
  • testing : The vaccine has been allowed to be tested on children between the ages of 5 and 18. Sick children are also to be included in the test.

Children’s population in India at a glance

  • More than 44 crore children are older than two years in the country
  • 12 crore children are in the age group of 12 to 17 years in the country
  • 20 to 30 lakh children are suffering from some disease

Sick children get priority

Sick children should get priority in vaccination. If such children come in the grip of infection, then their life can be in trouble. The risk to healthy children is low, but it is important to vaccinate them over time. -Doctor. Gagandeep Kang, Scientist, Christian Medical College, Vellore

.

Leave a Reply